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ORIGINAL ARTICLE
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Abstract
Objective: A non-synonymous single nucleotide polymorphism (nsSNP, rs2233434, Val194Ala) in
the NFKBIE (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor,
epsilon) gene is known to be a rheumatoid arthritis (RA) susceptibility polymorphism in the
Japanese RA population and could be closely associated with nuclear factor kappaB (NF-kB)
activity. Inflammation caused by RA is sometimes associated with changes in expression levels
of MTX (methotrexate) pathway-related genes. It is of interest to examine whether the NFKBIE
gene had any influences on the mode of MTX action.
Methods: Both knockdown of NFKBIE gene expression and overexpression of wild-type NFKBIE
and Val194Ala mutation were performed. A transfected human RA synovial cell line was
cultured and then gene expressions in the MTX pathway were measured. In addition, we
measured the uptake and efflux of MTX derivatives under the NFKBIE knockdown condition.
Results: Knockdown of NFKBIE reduced the mRNA for SLC19A1, a main MTX membrane
transporter, and the intracellular accumulations of MTX derivatives. Moreover, our experiments
also confirmed that overexpression of Val194Ala mutant NFKBIE decreased the SLC19A1 mRNA
when compared to that of wild-type NFKBIE.
Conclusions: We suggest that the impairment of NFKBIE gene function can reduce the uptake of
MTX into cells, suggesting that the gene is an important factor for the RA outcome.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory
disease that affects many tissues and organs, which is especially
characterized by persistent synovial tissue inflammation, leading
to the progressive joint disorder. In most RA patients, the
activation of nuclear factor kappaB (NF-kB), a hallmark of
inflammatory responses, plays an important role in the expression
of cytokines in the synovial tissue [1–3].
Methotrexate (MTX) is the most commonly used anchor drug
for treating RA. MTX is a folate analog, and its anti-rheumatic
mechanism has been discussed; the effect of MTX in vivo may
be mediated by reducing cell proliferation, increasing the rate of
apoptosis of T cells, and endogenous adenosine release; altering
the expression of cellular adhesion molecules; and influencing
the production of cytokines, humoral responses, and bone
formation [4].
A non-synonymous single nucleotide polymorphism (nsSNP,
rs2233434, Val194Ala) in the NFKBIE (nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor, epsilon) gene
has been reported to be an RA susceptibility polymorphisms using
a large-scaled genome-wide association study (GWAS) meta-
analysis in Japanese RA patients [5]. NFKBIE encodes I kappaB-
epsilon (IkBe), a member of the Inhibitor of kappaB (IkB) family
and its mRNA is widely expressed in different human tissues.
Additionally, the gene is known to inhibit the nuclear translocation
of NF-kB by binding to NF-kB proteins [6,7]. For this reason, the
risk haplotype of this nsSNP in NFKBIE has been reported to
show an enhancement of NF-kB activity in transfected cells
compared with the wild-type construct [8], following changes in
IkBe structure. In a study on the use of human peripheral blood
cells, Blits et al. observed that the expressions of MTX pathway
genes were increased in MTX-naive RA patients compared to
those of healthy controls [9]. Additionally, from the study using
synovial tissues obtained from RA patients, Stamp et al. noted a
negative correlation between the ESR (erythrocyte sedimentation
rate) and expressions levels of some MTX pathway genes [10].
These findings led us to wonder whether MTX pathway genes are
influenced by the NFKBIE gene.
In the present study, we hypothesized that NFKBIE may play a
role in regulating the expression levels of MTX pathway genes (i.e.
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drug membrane transporters and MTX-metabolizing enzymes). To
test our hypothesis, we examined the effect of knockdown of
NFKBIE or overexpression of wild-type NFKBIE and the mutant
(Val194Ala) NFKBIE on the gene expression levels of ‘‘drug
membrane transporters’’ that are closely related to the intracellular
accumulations of MTX in a human RA synovial cell line. We also
performed an investigation of ‘‘MTX-metabolizing enzyme’’
expression in the similar culture conditions. Knockdown of
NFKBIE expression resulted in down-regulation of SLC19A1
(solute carrier family 19 (folate transporter), member 1) expression
and intracellular accumulations of MTX derivatives. These results
suggest that impairing the effect of the NFKBIE gene may reduce
cellular uptake of MTX by down-regulating SLC19A1 expression.
Materials and methods
Cell culture
MH7A, a human RA synovial cell line, was purchased from Riken
Cell Bank (Tsukuba, Japan). MH7A is established by transfection
with the SV40 T antigen, and the cells are fibroblast-like
synoviocytes [11]. Cells were cultured in RPMI 1640 medium
(Sigma-Aldrich, Tokyo, Japan) containing 10% heat-inactivated
fetal bovine serum (FBS) (Gibco, Tokyo, Japan) in a humidified
incubator at 37C under 5% CO2. For experiments, MH7A was
trypsinized and passaged to 24-well dishes.
Chemicals
MTX, TNF-a, and IL-1b were purchased from Sigma-Aldrich.
Stock solutions of MTX (dissolved in 0.1 N NaOH and then diluted
in PBS), TNF-a, and IL-1b (diluted in PBS) were stored at20C.
For these drugs, working concentrations were prepared by diluting
stock solutions in a culture medium immediately before use.
Small interfering RNA (siRNA) transfection
To knockdown endogenous NFKBIE, cells were transfected with
20 pmol ON-TARGETplus NFKBIE siRNA (Dharmacon, Tokyo,
Japan) using Lipofectamine 2000 (Invitrogen, Tokyo, Japan).
Non-targeting control siRNA (Dharmacon) was used as a trans-
fection control and knockdown efficiency was examined by
reverse transcription quantitative real-time PCR (qRT-PCR). Cells
were plated at 0.75 105 cells/well and cultured for 24 h; then the
cells were transfected for 24 h. Subsequently, they were incubated
with or without 0.01, 0.1, 1, 5, and 10 mM MTX for 24 h in the
presence or absence of 20 U/mL IL-1b and 20 U/mL TNF-a.
Measurement of the uptake and efflux of MTX derivatives
After washing the cells with PBS, the cells were incubated in
the presence of 5 mM fluorescein methotrexate (Life
Technologies, Tokyo, Japan), an MTX derivative, for 5 h. In
another experiment, pulse chase analysis of the efflux of the
MTX derivative was performed. Two groups of transiently
transfected cells were incubated with 5 mM MTX derivatives
for 5 h and then washed with PBS, followed by chase for 0
and 6 h exclusively in RPMI supplemented with 10% FBS. On
the basis of these results, we studied differences in the efflux
of the MTX derivative between control and NFKBIE knock-
down cells. Before analysis, cells were treated with trypsin
(Wako, Osaka, Japan) to obtain a single cell suspension.
Intracellular accumulation of MTX derivatives was measured
with a Cell Lab Quanta SC (Beckman Coulter) flow cytometer
and mean fluorescence intensities was calculated on the basis
of our arbitrary drawing regions on the histogram. As a result,
at least 6000 cells were evaluated.
Plasmid constructs and preparations
The full coding IkBe clone was constructed by fusing two
overlapping cDNAs for residue 26-807 from HEK293, for residue
793-1528 from MH7A with appropriate primer pairs (HEK293
forward: 50-ATG AAT CAA CGA AGG AGT GAG TCA AGG
CC-30, HEK293 reverse: 50-GTG TCT CCG TCC TCG GAG
ATG TAA GTG AGT GC-30; MH7A forward: 50-CGA GGA
CGG AGA CAC GCT GGT CCA CCT GGC AGT GA-30, MH7A
reverse: 50-TCA GTC GGT ACA CAG CAG CAG TTT CCC
TG-30) and KOD-Plus-Neo (TOYOBO). PCR products were
inserted into the pFLAG-CMV5 vector, which was generated by
replacing the Myc-tag of pMyc_CMV5 (a gift from Dr. David W.
Russell in UT Southwestern Medical Center, Dallas, TX) with a
Flag-tag, between HindIII and BamHI using the 5 In-Fusion HD
Enzyme Premix (Clontech, Shiga, Japan). The 581T4C
(Val194Ala) mutation was generated using the 5 In-Fusion
HD Enzyme Premix with the wild-type NFKBIE construct as a
template and the following primers (forward: 50-CGG GAC CCG
CCA AGG AAC CAC AGG AGA A-30; reverse: 50-CCT TGG
CGG GTC CCG GAG GAT GGG TGC A-30). Both wild-type and
mutated constructs were sequenced to verify that only the desired
constructs were present.
To overexpress wild-type or Val194Ala mutant NFKBIE, cells
were plated at 1.50 105 cells/well and cultured for 24 h. Cells
were transfected with 0.8 mg of plasmid DNA using Lipofectamine
2000 and empty pFLAG-CMV5 plasmid was used as the
transfection control (Mock) and then incubated for 18 h. After
changing the medium, the cells were incubated with or without
0.01, 0.1, 1, 5, and 10 mM MTX for 24 h in the presence or
absence of both 20 U/mL IL-1b and 20 U/mL TNF-a.
Quantitative reverse transcription PCR (qRT-PCR)
Total RNA extracted using TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions was used as a template for
one-step qRT-PCR with One Step SYBR PrimeScript RT-
PCR Kit II (Perfect Real Time) (TaKaRa, Shiga, Japan).
Amplification of the cDNA was performed using specific
oligonucleotide primers (Table 1) with Applied Biosystems
7500 Real-Time PCR system according to the supplier’s
recommendations. The program used for qRT-PCR amplification
included a 10-s inactivation of reverse transcriptase at 95 C, a 5-
s denaturation step at 95C, a 10-s annealing step at 58C, a 34-s
extension step at 72C (for 35 cycles), and a dissociation step
(15 s at 95C, 60 s at 60C, and 15 s at 95C). To determine the
specificity of each primer set, we performed melting curve
analysis after the completion of PCR amplification. The
accumulated levels of fluorescence were analyzed by the fit-
point method after the melting curve analysis. The expression
levels of mRNA were calculated using the 2DDCT method as
previously described [12]. NFKBIE, SLC19A1, ABCC1 (ATP-
binding cassette, sub-family C (CFTR/MRP), member 1),
ABCC5 (ATP-binding cassette, sub-family C (CFTR/MRP),
member 5), ABCG2 (ATP-binding cassette, sub-family G
(WHITE), member 2), FPGS (folylpolyglutamate synthase),
GGH (gamma-glutamyl hydrolase (conjugase, folylpolygamma-
glutamyl hydrolase)), DHFR (dihydrofolate reductase), TYMS
(thymidylate synthetase), MTHFR (methylenetetrahydrofolate
reductase (NAD(P)H)), and ATIC (5-aminoimidazole-4-carbox-
amide ribonucleotide formyltransferase/IMP cyclohydrolase)
gene mRNA levels were normalized with housekeeping gene
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) in each
sample.
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Total cell and viable cell counting
All cells in one well were collected after trypsinization. The cell
proliferation and viability were evaluated by counting the cells and
0.4% trypan blue (Wako) staining using the TC20 automated cell
counter (Bio-Rad Laboratories) according to the manufacturer’s
instructions. To evaluate the number of total cells and live cells,
we mixed the cell suspension 1:1 with 0.4% trypan blue solution
and pipetted 10 mL of this mixture onto a counting slide specific
for the TC20 automated cell counter.
Statistical analysis
All of the data were compared using Student’s t-test.
Results
Effects of NFKBIE knockdown by siRNA in drug membrane
transporters
To investigate the effects of NFKBIE knockdown on the
expressions of drug membrane transporters we confirmed expres-
sion by qRT-PCR. The NFKBIE expression level in the NFKBIE
knockdown group was almost 12–20% of the control expression
level under many conditions (Figure 1A). NFKBIE knockdown
could reduce the SLC19A1 expression (Figure 1B), whereas there
was no obvious alteration in the expressions of the ABC
transporters (Figure 1C–E).
Uptake and efflux of MTX derivatives under the knockdown
condition of NFKBIE by siRNA
Because several research studies have estimated that both the
uptake and accumulation of MTX derivatives in mammalian
cells are strongly affected by differences in the SLC19A1
expression [13–18], we examined both the uptake and efflux
of MTX derivatives and measured functional SLC19A1
expressed in transfectant MH7A in an inflammatory milieu
that mimics RA joints using flow cytometry. To determine
whether knockdown of NFKBIE by siRNA affects the
accumulation of MTX, MH7A was transfected and pre-treated
with cytokines; then MTX derivative uptake into cells was
examined. As shown in Figure 2(A) and (B), knockdown of
NFKBIE reduced the accumulation of MTX derivatives. But,
we found no significant differences in the efflux of MTX
derivatives between the control and NFKBIE knockdown
(Figure 2C).
Effects of NFKBIE Val194Ala overexpression on drug
membrane transporters
We transiently overexpressed either wild-type, Val194Ala or
Mock into MH7A and incubated as described above. Small but
statistically significant differences in the SLC19A1 expression
levels at a significant MTX level (45mM) were noted; the
wild-type overexpression group exhibited more SLC19A1
expression than the Val194Ala overexpression group (Figure
3A). In addition, this graph shows that overexpression of the
wild-type gene had significantly more upregulated expression
of SLC19A1 than NFKBIE Val194Ala under no cytokines
condition (Figure 3A). There were no statistical changes
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MTX-metabolizing enzymes expressions under knockdown
and overexpression conditions
The expression levels of MTX-metabolizing enzymes including
FPGS, GGH, TYMS, DHFR, MTHFR, and ATIC were
observed under different conditions (Figures 4 and 5). Our
data indicate that the expressions of MTX-metabolizing
enzymes except for FPGS had no significant associations
either between the control and NFKBIE knockdown, or
between wild-type and Val194Ala NFKBIE overexpression
(Figures 4 and 5). In FPGS expression, we observed that there
was a general tendency towards a difference between the
overexpression of the wild-type and Val194Ala gene in the
overexpression study alone (Figure 5A).
Discussion
We have shown that, in a human RA synovial cell line,
knockdown of NFKBIE expression results in the down-regulation
of SLC19A1 but does not influence ABC transporters or MTX-
Figure 1. Effects of NFKBIE knockdown on the expression levels of SLC19A1 and ABC transporters. Quantitative gene expressions of NFKBIE (A),
SLC19A1 (B), ABCC1 (C), ABCC5 (D), and ABCG2 (E) genes in control (gray) and NFKBIE knockdown (black) MH7A treated with or without 0.01,
0.1, 1, 5, and 10 mM methotrexate (MTX) application for 24 h in the presence or absence of 20 U/mL IL-1b and 20 U/mL TNF-a were measured by
qRT-PCR. Statistical significance was analyzed using the unpaired t-test (*p50.05). The results are presented as the mean ± standard error of the mean
(SEM) of at least three independent experiments.
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metabolizing enzymes. In addition, we have demonstrated that
NFKBIE knockdown of MH7A results in lower intracellular
accumulation of MTX derivatives than control MH7A.
Furthermore, overexpression of the Val194Ala mutant NFKBIE
resulted in decreased SLC19A1 levels when compared to that of
wild-type NFKBIE both above a specified MTX concentration
(more than 5 mM) with cytokines and at a cytokine-free
environment. ABC transporters and MTX-metabolizing enzymes
expressions except for FPGS, lacked a significant difference
between the overexpressed wild-type and Val194Ala NFKBIE
constructs. In FPGS gene expression, there was a tendency of
slight upregulation in the Val194Ala overexpression group
compared to the wild-type overexpression group.
IkBe is known to be expressed in human synovial cells [19].
In IkBe-deficient mice, the expression of inflammatory cytokines,
such as IL-6, IL-1b, IL-1a, and IL-1Ra, was constitutively
increased compared to that in wild-type mice; also, there was
increased B cell proliferation and survival [20,21]. On the other
hand, overexpression of IkBe with the nsSNP (rs2233433;
Val194Ala) vector had an enhancement of NF-kB activity
compared with the wild-type construct [8].
SLC19A1, a reduced folate carrier, is the most dominant folate
transporter with high affinity for reduced folates and the antifolate
drug MTX, but it has very low affinity for folic acid [22–24]. MTX
enters the mammalian cells largely via SLC19A1 and it effluxes
from cells via ATP-binding cassette (ABC) transporters, which is to
say that cellular uptake of MTX via SLC19A1 is considered as the
initial step for exerting its effect [25,26]. Once entering the cells
mainly via SLC19A1, MTX is polyglutamated by FPGS, retained as
a polyglutamated form within the cell [27]. Polyglutamated MTX
Figure 2. Uptake and efflux of a methotrexate (MTX) derivative under knockdown of NFKBIE by siRNA in MH7A. MH7A cells were cultured for 24 h,
and then transfected for 24 h. They were further incubated with 20 U/mL IL-1b and 20 U/mL TNF-a for 24 h. After washing the cells with PBS, the cells
were incubated in the presence of 5 mM of MTX derivatives for 5 h. The uptake of MTX derivatives was quantified by measuring the fluorescence
emission for each sample. (A) The representative histogram of control (blue) and knockdown of NFKBIE (dark red). The mean fluorescent intensity
(MFI) per cell, expressed in arbitrary units, was then determined using a flow cytometer. (B) The summary results. In addition to these experiments, after
incubating with MTX derivatives (5 mM) for 5 h and washing cells with PBS, cells were chased for 6 h exclusively in RPMI supplemented with 10%
FBS. Subsequently, the MFI per cell was measured at 0 and 6 h. On the basis of these results, differences in the efflux of MTX derivatives between
control and NFKBIE knockdown were studied (C). Each column and its corresponding vertical lines represent the mean and the standard error of the
mean (SEM) of triplicate cultures. Statistical significance was analyzed with the unpaired t-test (*p50.05).
DOI: 10.3109/14397595.2015.1112481 Impaired NFKBIE gene function 511
can be reversed to the nonpolyglutamated form by GGH and then
extruded from cells via ABC transporters [28]. Monoglutamated
MTX and polyglutamated MTX have equal binding affinity for
DHFR, but polyglutamated MTX rather exerts a stronger inhibition
of DHFR, TYMS, and ATIC [29–31]. DHFR plays a key role in
converting dihydrofolate (DHF) to their active form tetrahydrofo-
late (THF), which is needed for several one-carbon transfer
reactions in de novo synthesis of varieties of essential metabolites
(e.g. purines, pyrimidines, etc.) [32]. TYMS is an important gene in
de novo pyrimidine synthesis and for DNA synthesis and repair
[33]. ATIC is an enzyme involved in the de novo purine synthesis
pathway that is responsible for the conversion of AICAR into
formyl-AICAR (FAICAR) [34]. Intracellular accumulation of
AICAR owing mainly to direct inhibition of ATIC by polygluta-
mated MTX leads to increased intracellular adenosine, a potent anti-
inflammatory agent, and its consequent release to the extracellular
space [35]. Additionally, MTHFR is thought to be a key enzyme that
regulates DNA synthesis and DNA methylation [36]. Although,
MTHFR is not directly inhibited by MTX or by polyglutamated
MTX, its expression level is recognized to be involved in MTX
chemosensitivity [37].
Within the cell, folates, known as essential vitamins that serve
as one-carbon donors in many biosynthetic pathways, also
undergo polyglutamylation catalyzed by FPGS. As a result,
polyglutamylated folates enhanced the cellular retention and thus
exert stronger effects [38]. The mRNA level of FPGS is
upregulated by cell proliferation and reduced by cell maturation
[39,40]. The results obtained in synovial cells demonstrated that
activated NF-kB pathways play an important role in cell
proliferation [2]. We measured cell proliferation of overexpressing
wild-type NFKBIE and Val194Ala NFKBIE by a cell counter.
As a result, it was found that cells overexpressing Val194Ala
constructs have a tendency for more cell-proliferative activity
than those overexpressing wild-type constructs (Appendix 1).
This observation is in agreement with our result of FPGS
expression in an overexpression study.
The ABC transporter genes including ABCC1, ABCC5, and
ABCG2 utilize the energy of ATP hydrolysis to translocate their
substrates across biological membranes [24]. We have chosen
these ABC transporter genes because, in previous studies,
transfectant cells overexpressing ABCC1 and ABCC5 displayed
more MTX resistance levels than those of other ABC transporters
Figure 3. Effects of overexpression of Mock, wild-type NFKBIE, and Val194Ala mutant NFKBIE on the expressions of SLC19A1 and the ABC
transporters. Quantitative gene expressions of SLC19A1 (A), ABCC1 (B), ABCC5 (C), and ABCG2 (D) genes in Mock (white), overexpression of wild-
type NFKBIE (gray), and Val194Ala mutant NFKBIE (black). Those cells were treated with or without 0.01, 0.1, 1, 5, and 10 mM methotrexate (MTX)
application for 24 h in the presence or absence of 20 U/mL IL-1b and 20 U/mL TNF-a. The expression levels of each gene were measured by qRT-PCR.
Statistical significance was analyzed using the unpaired t-test (*p50.05). The results are presented as the mean ± standard error of the mean (SEM) of at
least three independent experiments. *p50.05 versus wild-type.
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as well as because ABCG2 is a transporter of both MTX
monoglutamates as well as di- and triglutamate conjugates of
MTX, which is an important feature differentiating ABCG2 from
other transporters [24]. We found little differences in the mRNA
expressions of those efflux transporters.
Although, the molecular mechanisms for the reduction of
SLC19A1 expression are still unknown, our results strongly
suggest that impairment of NFKBIE gene function suppressed
SLC19A1 expression. Studies in mouse synovial cells show that
SLC19A1 expression was down-regulated by inflammatory com-
ponents, such as IL-6 [18]. In RA patients, there was a significant
negative correlation between SLC19A1 expression and ESR [10].
These studies lead us to believe that SLC19A1 down-regulation is
associated with inflammation. MTX itself is closely related to
SLC19A1 expression [18,41]. More recently, it has become more
obvious that MTX induces proinflammatory cytokines, such as
IL-6, which may be one of the reasons MTX has some effects on
the expression of SLC19A1 [42,43]. As previously mentioned,
Figure 4. Effects of NFKBIE knockdown on the expressions of MTX-metabolizing enzymes. Quantitative gene expressions of FPGS (A), GGH (B),
DHFR (C), TYMS (D), MTHFR (E), and ATIC (F) genes in control (gray) and NFKBIE knockdown (black) MH7A. Those cells were treated with or
without 0.01, 0.1, 1, 5, and 10 mM methotrexate (MTX) application for 24 h in the presence or absence of 20 U/mL IL-1b and 20 U/mL TNF-a. The
expression levels of each gene were measured by qRT-PCR. Statistical significance was analyzed by the unpaired t-test (*p50.05). The results are
presented as the mean ± standard error of the mean (SEM) of at least three independent experiments.
DOI: 10.3109/14397595.2015.1112481 Impaired NFKBIE gene function 513
IkB-deficient mice have increased expression of some inflamma-
tory cytokines [20,21]. SLC19A1 expression is reportedly
upregulated under the folate-restricted condition, but increased
folate availability suppresses its expression [44,45]. Jansen et al.
identified that, upon growth in a low folate medium, a mutation in
the SLC19A1 gene results in increasing affinity of transporters for
(anti)folates and that in folate-replete medium, the preferential
folate transport results in a markedly expanded intracellular folate
pool impairing antifolate metabolism [46]. We demonstrated that
in an overexpression study, there were no significant differences in
the SLC19A1 expression level between wild-type and Val194Ala
at a low MTX concentration (0.01–1 mM) of cytokines. Because
the medium used in our study contained far (approximately
100 times) higher levels of folate than the in vivo folate level [46],
Figure 5. Effects of overexpression of Mock, wild-type NFKBIE, and Val194Ala mutant NFKBIE on MTX-metabolizing enzyme expressions.
Quantitative gene expressions of FPGS (A), GGH (B), DHFR (C), TYMS (D), MTHFR (E), and ATIC (F) genes in Mock (white), overexpression of wild-
type NFKBIE (gray) and Val194Ala mutant NFKBIE (black). Those cells were treated with or without 0.01, 0.1, 1, 5, and 10 mM methotrexate (MTX)
application for 24 h in the presence or absence of 20 U/mL IL-1b and 20 U/mL TNF-a. The expression levels of each gene were measured by qRT-PCR.
Statistical significance was analyzed using the unpaired t-test (*p50.05). The results are presented as the mean ± standard error of the mean (SEM) of at
least three independent experiments. *p50.05 versus wild-type.
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the dose-effect relationship between MTX and SCL19A1 suppres-
sion may also be shifted to the higher concentration side.
In conclusion, the results obtained in this paper support the
hypothesis that NFKBIE may play a role in regulating the
expression of some MTX pathway genes in a cell culture model
which reproduced the synovial cell context in RA joints as
accurately as possible by the addition of inflammatory cytokines,
and the results may be helpful for further understanding of the
MTX-resistant mechanism. This study provides an important
contribution because these findings were detected in NFKBIE
(rs2233434, Val194Ala), an RA susceptibility gene locus in a
large-scaled GWAS meta-analysis for RA in the Japanese
population. The present study suggests that impairment of
NFKBIE gene function may result in the down-regulation of
SLC19A1, reduction of MTX uptake, and MTX-resistance,
although further research with additional in vivo studies is also
needed.
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Appendix 1. Effects of overexpression of Mock, wild-type NFKBIE, and Val194Ala mutant NFKBIE on cell proliferation
The effects of in Mock (white), overexpression of wild-type NFKBIE (gray), and Val194Ala mutant NFKBIE (black) on cell proliferation were
measured. MH7A cells were plated at 1.50 105 cells/well and cultured for 24 h. In turn, cells were transfected for 18 h as explained above. After
changing medium, they were incubated with or without 0.01, 0.1, 1, 5, and 10 mM methotrexate (MTX) for 24 h in the presence or absence of both 20 U/
mL IL-1b and 20 U/mL TNF-a. All cells in a single well were collected after trypsinization and measured by a TC20 automated cell counter. The
number of cells was used to determine the proliferation of transfected MH7A. The results are presented as the mean ± standard error of the mean (SEM)
of at least four independent experiments. Statistical significance was analyzed by the unpaired t-test (*p50.05). *p50.05 versus wild-type.
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